PT1011706E - Metodo para impedir aterosclerose acelerada utilizando receptor soluvel de produto final de glicacao avancada (srage) - Google Patents

Metodo para impedir aterosclerose acelerada utilizando receptor soluvel de produto final de glicacao avancada (srage)

Info

Publication number
PT1011706E
PT1011706E PT98939876T PT98939876T PT1011706E PT 1011706 E PT1011706 E PT 1011706E PT 98939876 T PT98939876 T PT 98939876T PT 98939876 T PT98939876 T PT 98939876T PT 1011706 E PT1011706 E PT 1011706E
Authority
PT
Portugal
Prior art keywords
advanced
subject
glycacao
aterosclerosis
srage
Prior art date
Application number
PT98939876T
Other languages
English (en)
Inventor
David Stern
Ann Marie Schmidt
Original Assignee
Trustees Of Columbia U In The
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Of Columbia U In The filed Critical Trustees Of Columbia U In The
Publication of PT1011706E publication Critical patent/PT1011706E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Producing Shaped Articles From Materials (AREA)
  • Seasonings (AREA)
  • Special Spraying Apparatus (AREA)
PT98939876T 1997-08-05 1998-08-05 Metodo para impedir aterosclerose acelerada utilizando receptor soluvel de produto final de glicacao avancada (srage) PT1011706E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/905,709 US7101838B2 (en) 1997-08-05 1997-08-05 Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts

Publications (1)

Publication Number Publication Date
PT1011706E true PT1011706E (pt) 2004-04-30

Family

ID=25421326

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98939876T PT1011706E (pt) 1997-08-05 1998-08-05 Metodo para impedir aterosclerose acelerada utilizando receptor soluvel de produto final de glicacao avancada (srage)

Country Status (11)

Country Link
US (2) US7101838B2 (pt)
EP (1) EP1011706B1 (pt)
JP (2) JP4426090B2 (pt)
AT (1) ATE253929T1 (pt)
AU (1) AU758252B2 (pt)
CA (1) CA2299467A1 (pt)
DE (1) DE69819751T8 (pt)
DK (1) DK1011706T3 (pt)
ES (1) ES2210800T3 (pt)
PT (1) PT1011706E (pt)
WO (1) WO1999007402A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
AU765719B2 (en) * 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
JP2003507013A (ja) * 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのＲＡＧＥへの結合を阻害する方法及びその結果
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US7919670B1 (en) 2000-08-14 2011-04-05 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
CA2440042C (en) 2001-03-05 2011-09-27 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
CN1235583C (zh) 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
EP1482931B1 (en) * 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
MXPA05001758A (es) * 2002-08-16 2005-08-19 Wyeth Corp Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage).
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
WO2006012415A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
EP1776459A1 (en) * 2004-08-03 2007-04-25 Transtech Pharma, Inc. Rage fusion proteins and methods of use
ES2473587T3 (es) * 2004-08-03 2014-07-07 Transtech Pharma, Inc. Proteínas de fusión de RAGE y métodos de uso
EP1799700A4 (en) 2004-09-27 2009-02-11 Centocor Inc SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES
EP1869464A4 (en) * 2005-03-17 2009-12-02 Univ Columbia RAGE-DIAPHANOUS INTERACTION AND CORRESPONDING COMPOSITIONS AND METHODS
EP1963786B1 (en) * 2005-12-23 2013-07-24 GCoder Systems AB Positioning pattern
WO2007094926A2 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
EA017291B1 (ru) 2006-05-05 2012-11-30 Транстек Фарма, Инк. Белки слияния на основе rage, их композиции и способы их применения
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
US8398977B2 (en) 2007-06-14 2013-03-19 Galactica Pharmaceuticals, Inc. Rage fusion proteins
CL2008002054A1 (es) 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
AR067537A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
CN102037119B (zh) 2008-05-23 2015-06-24 Siwa有限公司 促进再生的方法、组合物及设备
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
WO2012047629A2 (en) 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2012135616A1 (en) * 2011-03-31 2012-10-04 Siwa Corporation Vaccination against advanced glycation end-products
US9175062B2 (en) * 2012-01-03 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human soluble receptor for advanced glycation end products (sRAGE), methods of preparing human sRAGE, and treatment methods using sRAGE
KR20150064743A (ko) 2012-10-05 2015-06-11 트랜스테크 파르마 엘엘씨 경도 및 중등도 알츠하이머 병의 치료
EP2965092A1 (en) * 2013-03-08 2016-01-13 Zora Biosciences OY Non-high density lipoprotein derived cvd markers
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
IL283726B2 (en) 2016-02-19 2025-05-01 Siwa Corp A preparation containing an antibody to advanced glycation end products (AGE) for use in the treatment of breast cancer
EP3443007A1 (en) 2016-04-15 2019-02-20 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
BR112019021471A2 (pt) 2017-04-13 2020-05-12 Siwa Corporation Anticorpo monoclonal humanizado de produto final da glicação avançada
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物
JP2023547479A (ja) * 2020-10-30 2023-11-10 シェンチェン、プロトゲン、リミテッド 疾患の治療におけるヒト血清アルブミンの使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
US5605885A (en) * 1988-05-05 1997-02-25 Entremed, Inc. Method for stimulating the immune system
EP0515698B1 (en) 1990-12-07 1998-07-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for producing D-alpha-amino acids
CN1134803A (zh) 1996-01-24 1996-11-06 沈阳市大东副食品商场 乘车游乐自选购物系统
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5688653A (en) 1996-06-27 1997-11-18 The Picower Institute For Medical Research 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
JP2003507013A (ja) 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのＲＡＧＥへの結合を阻害する方法及びその結果

Also Published As

Publication number Publication date
JP2001513511A (ja) 2001-09-04
HK1030742A1 (en) 2001-05-18
EP1011706A1 (en) 2000-06-28
US7101838B2 (en) 2006-09-05
US20070099829A1 (en) 2007-05-03
JP2010065040A (ja) 2010-03-25
EP1011706B1 (en) 2003-11-12
AU758252B2 (en) 2003-03-20
WO1999007402A1 (en) 1999-02-18
DE69819751D1 (de) 2003-12-18
JP4426090B2 (ja) 2010-03-03
DK1011706T3 (da) 2004-03-22
US20010039256A1 (en) 2001-11-08
EP1011706A4 (en) 2001-10-17
DE69819751T8 (de) 2005-01-05
CA2299467A1 (en) 1999-02-18
JP4976475B2 (ja) 2012-07-18
ATE253929T1 (de) 2003-11-15
AU8823998A (en) 1999-03-01
US7494972B2 (en) 2009-02-24
ES2210800T3 (es) 2004-07-01
DE69819751T2 (de) 2004-09-30

Similar Documents

Publication Publication Date Title
DK1011706T3 (da) Anvendelse af opløselig receptor for endeprodukter med fremskreden glycosylering (sRAGE) til modvirkning af accelereret atherosklerose
GC0000109A (en) System and method for delineating spatially dependent objects, such as hydrocarbon accumulations from seismic data.
PL340659A1 (en) Spheroides, method of obtaining them and pharmacological compositions
IL125928A0 (en) Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and pharmaceutical compositions for inhibiting the same
WO1996039193A3 (en) Drug mitochondrial targeting agents
EP0989751A3 (en) Information distributing apparatus and information distributing method, information receiving apparatus and information receiving method as well as information receiving and distributing method
AU6861798A (en) Method and arrangement for automatic data acquisition of forms
AU1218000A (en) Polyspecific binding molecules and uses thereof
WO1996015149A3 (en) Methods and compositions for screening for presynaptic calcium channel blockers
CA2374521A1 (en) Test question response verification system
EP1017001A3 (en) Method and apparatus for selling digital contents
WO1999003822A8 (en) Bicyclic metabotropic glutamate receptor ligands
FR2795527B1 (fr) Systeme de prospection sismique sous-marine, notamment pour grands fonds
EP0919920A3 (en) Method for estimating statistics of properties of memory system transactions
DK0969873T3 (da) Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf
DE59600580D1 (de) Verfahren zur lastmessung
FR2770927B1 (fr) Machine de chargement pour deplacer des objets oblongs etroitement voisins, notamment des assemblages combustibles
WO1998000770A3 (en) Encryption enhancement system
DE69634943D1 (de) Verbesserte Festpartikeldispersionen für Aufzeichnungselemente
DK0937092T3 (da) Faste bærematrixer indeholdende et oligosaccharid, som binder toksiner
CA2440399A1 (en) Epitope testing using hla
BG102229A (en) Endothelium receptor antagonists
MX9601930A (es) Anticuerpos anti-idiotipicos los cuales inducen una respuesta inmune contra el receptor de crecimiento epidermico.
BR9713395A (pt) paração de um sal de amÈnio quaternário
NZ237533A (en) Monoclonal antibodies which bind to oncostatin m, cell lines producing them